Red Light Therapy
introducing Eyerising Myproclear—an innovative at-home device designed to provide low-level red-light therapy directly to the retina. This technology is set to revolutionize the way we approach myopia treatment and offers hope to countless short-sighted children striving for better vision and a brighter future.
What are the risks with Myopia?
Spending extended periods indoors can be enjoyable, but the increasing amount of time spent indoors has contributed to a rapid rise in myopia cases. Our eyesight plays a crucial role in our ability to learn, navigate the world, and significantly affects our potential for leading fulfilling and productive lives.
When a child is diagnosed with myopia, taking steps to slow its progression from an early stage becomes imperative. The sooner myopia is managed, the greater the likelihood of preserving long-term vision and ensuring a high quality of life as they transition into adulthood. However, it's important to note that while there are various treatments available for myopia, some of them can be invasive, making them less suitable for children, particularly those who are very young. This limitation can leave parents and their child's healthcare provider with limited options to explore.
Red Light Therapy with Eyerising's Myopia Management Device
Published clinical trials have confirmed the effectiveness of the Eyerising Myopia Management Device in treating myopia, demonstrating a remarkable reduction in its progression by up to 87.7%.
Furthermore, the ongoing comprehensive clinical trial program for RLRL therapy has substantiated its efficacy and safety. The outcomes, documented in prominent peer-reviewed scientific journals, reveal that when adhered to with over 75% compliance, RLRL therapy effectively manages and controls the progression of myopia.